This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
ST. PETERSBURG, Fla.,
April 9, 2013 /PRNewswire/ -- Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announced in-vitro study results suggesting ACTICOAT Silver-Coated Antimicrobial Dressings are bactericidal against some antibiotic resistant organisms carrying the NDM-1 enzyme, often referred to as 'superbugs'.
An in-vitro laboratory study showed ACTICOAT Dressings, containing patented Nanocrystalline Silver technology, can kill the antibiotic resistant enzyme,
New Delhi metallo-beta-lactamase 1 (NDM-1 bacteria strain)
3 which is carried by four of the same CRE bacteria cited by the CDC1. In this study, ACTICOAT Dressings killed Escherichia coli and Klebsiella spp.,
3 which are responsible for most carbapenem resistance in
the United States1.
The Centers for Disease Control (CDC) issued statements recently to warn the public about antibiotic resistant organisms like carbapenem-resistant Enterobacteriaceae (CRE), raising concerns about the rise in the prevalence of these organisms and their associated high mortality rates
1. While the prevalence of CRE varies by geographic region, CRE organisms can spread their resistant genes to common bacteria, potentially resulting in the spread of untreatable infections.
Reducing the spread of CRE is challenging for hospitals, rehabilitation facilities and nursing homes because these antibiotic resistant bacteria develop resistance to even the most powerful antibiotics which are often reserved as a last resort. According to the CDC, almost all CRE infections happen to patients who are receiving serious medical care
Jose Vazquez, MD, FACP, FIDSA, Professor of Medicine, Division of Infectious Diseases,
Wayne State University School of Medicine, Senior Staff, Henry Ford Hospital,
Detroit, MI uses ACTICOAT Dressings in his practice. He says: "Any opening in the skin provides an entry point for antibiotic resistant organisms. I use ACTICOAT Dressings in my practice because they provide an antimicrobial barrier that helps protect wounds and incision sites from external contamination. I continue to see excellent clinical results because ACTICOAT Dressings are bactericidal against five strains of bacteria that carry the NDM-1 enzyme and 360+ pathogens including 188 strains of MRSA."
The Nanocrystalline Silver in ACTICOAT Dressings is different from the silvers used in other dressings because of its potency, fast kill action of 30 minutes, and broad spectrum activity. ACTICOAT provides bactericidal activity for up to seven days, so it helps protect patients with wounds or incisions from environmental contamination, even after they leave the hospital. ACTICOAT is contra-indicated in patients with known hypersensitivity to any of the components of the product. (If signs of a sensitivity reaction develop during use, treatment should be discontinued.)